Patents by Inventor John D. Lambris

John D. Lambris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Complement-mediated thrombophilic assay
    Patent number: 8563259
    Abstract: A method for assessing the presence of an acquired thrombophilia disorder in a patient exhibiting hypercoagulation is disclosed.
    Type: Grant
    Filed: June 25, 2008
    Date of Patent: October 22, 2013
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: John D. Lambris, Konstantinos Ritis
  • Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
    Patent number: 8445190
    Abstract: Methods for reducing or eliminating biomaterial-induced procoagulant activity in blood subjected to extracorporeal treatment that exposes the blood to the biomaterial are disclosed. The methods involve treatment of the blood, or the extracorporeal biomaterial, or both, with a complement inhibitor to inhibit C5a/C5aR-mediated tissue factor formation in the blood.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: May 21, 2013
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: John D. Lambris, Konstantinos Ritis
  • Structure of compstatin-C3 complex and use for rational drug design
    Patent number: 8442776
    Abstract: The structure of C3c in complex with the complement inhibitor, compstatin, and use of this information for rational design or identification of complement-inhibiting drugs are disclosed.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: May 14, 2013
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: John D. Lambris, Bert J. C. Janssen, Piet Gros
  • Treatment Of Sepsis Using Complement Inhibitors
    Publication number: 20130053302
    Abstract: Methods for the treatment of sepsis with complement inhibitors are disclosed. In particular, C3 inhibitors, such as Compstatin and Compstatin analogs, are administered at various times following the onset of sepsis to alleviate tissue damage and organ failure, which are hallmarks of the second, extravascular stage of sepsis. Combination therapies for comprehensive treatment of sepsis are also disclosed. Pharmaceutical compositions and kits for use in the methods are disclosed as well.
    Type: Application
    Filed: February 25, 2011
    Publication date: February 28, 2013
    Inventors: John D. Lambris, Fletcher B. Taylor, Florea Lupu, Gary Kinasewitz
  • METHODS OF TREATING OR PREVENTING PERIODONTITIS AND DISEASES ASSOCIATED WITH PERIODONTITIS
    Publication number: 20130034568
    Abstract: The present disclosure describes methods for preventing or treating periodontitis or diseases associated with periodontitis. The present disclosure also describes methods of screening for compounds that can be used to prevent or treat periodontitis or diseases associated with periodontitis.
    Type: Application
    Filed: January 24, 2011
    Publication date: February 7, 2013
    Inventors: Georgios Hajishengallis, John D. Lambris
  • Modified Compstatin With Peptide Backbone And C-Terminal Modifications
    Publication number: 20120178694
    Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds. The compounds comprise compstatin analogs having a constrained backbone at position 8 (glycine) and, optionally, specific substitutions for threonine at position 13.
    Type: Application
    Filed: May 3, 2010
    Publication date: July 12, 2012
    Inventors: John D. Lambris, Hongchang Qu
  • Potent Compstatin Analogs
    Publication number: 20120004393
    Abstract: Compounds comprising peptides and peptidomimetics capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds.
    Type: Application
    Filed: January 14, 2011
    Publication date: January 5, 2012
    Inventors: John D. LAMBRIS, Madan Katragadda
  • COMPSTATIN ANALOGS WITH IMPROVED ACTIVITY
    Publication number: 20110275150
    Abstract: Compounds comprising peptides and peptidomimetics capable of binding the C3 protein and inhibiting complement activation are disclosed. These compounds display improved complement activation-inhibitory activity as compared with currently available compounds. Isolated nucleic acid molecules encoding the peptides are also disclosed.
    Type: Application
    Filed: July 6, 2011
    Publication date: November 10, 2011
    Inventor: John D. LAMBRIS
  • METHOD OF INHIBITING BIOMATERIAL-INDUCED PROCOAGULANT ACTIVITY USING COMPLEMENT INHIBITORS
    Publication number: 20110269113
    Abstract: Methods for reducing or eliminating biomaterial-induced procoagulant activity in blood subjected to extracorporeal treatment that exposes the blood to the biomaterial are disclosed. The methods involve treatment of the blood, or the extracorporeal biomaterial, or both, with a complement inhibitor to inhibit C5a/C5aR-mediated tissue factor formation in the blood.
    Type: Application
    Filed: September 29, 2009
    Publication date: November 3, 2011
    Inventors: John D. Lambris, Konstantinos Ritis
  • Complement Inhibitors For Treatment Of Injury From Intracerebral Hemorrhage
    Publication number: 20110256136
    Abstract: Methods for treating or ameliorating the damage resulting from intracerebral hemorrhage are disclosed. The methods involve administration of a complement inhibitor to inhibit C3a or C5a formation or activity in the affected tissue. Pharmaceutical compositions suitable for use in the methods of the invention are also provided.
    Type: Application
    Filed: August 19, 2009
    Publication date: October 20, 2011
    Inventors: John D. Lambris, E. Sander Connolly, JR.
  • Compstatin analogs with improved activity
    Patent number: 7989589
    Abstract: Compounds comprising peptides and peptidomimetics capable of binding the C3 protein and inhibiting complement activation are disclosed. These compounds display improved complement activation-inhibitory activity as compared with currently available compounds. Isolated nucleic acid molecules encoding the peptides are also disclosed.
    Type: Grant
    Filed: September 22, 2003
    Date of Patent: August 2, 2011
    Assignee: The Trustees Of The University Of Pennsylvania
    Inventor: John D. Lambris
  • Method Of Treating Acute Respiratory Distress Syndrome
    Publication number: 20110142837
    Abstract: Methods for treating and/or alleviating acute respiratory distress syndrome in an individual diagnosed with or at risk of developing acute respiratory distress syndrome are disclosed. The methods comprise administering a therapeutically effective amount of a complement inhibitor or a TNF-alpha inhibitor to the individual, wherein the complement inhibitor or the TNF-alpha inhibitor reduces or prevents tissue factor production in alveolar neutrophils, thereby treating the ARDS, or delaying or preventing onset of ARDS.
    Type: Application
    Filed: July 17, 2008
    Publication date: June 16, 2011
    Applicants: TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, DEMOCRITUS UNIVESITY OF THRACE
    Inventors: John D. Lambris, Konstantinos Ritis
  • Structure Of Compstatin-C3 Complex And Use For Rational Drug Design
    Publication number: 20110060127
    Abstract: The structure of C3c in complex with the complement inhibitor, compstatin, and use of this information for rational design or identification of complement-inhibiting drugs are disclosed.
    Type: Application
    Filed: June 6, 2008
    Publication date: March 10, 2011
    Inventors: John D. Lambris, Bert J.C. Janssen, Piet Gros
  • Secreted Staphylococcus Aureus Proteins And Peptides For Use In Inhibiting Activation Of The Complement System
    Publication number: 20110046075
    Abstract: Compounds comprising peptides and peptide analogs capable of binding the C3 protein and inhibiting complement activation are disclosed. These compounds mimic the structure and activity of secreted Staphylococcus aureus proteins, Efb and the previously uncharacterized SAV1 155.
    Type: Application
    Filed: February 6, 2008
    Publication date: February 24, 2011
    Inventors: John D. Lambris, Brian V. Geisbrecht
  • COMPLEMENT INHIBITORS AS THERAPEUTIC AGENTS FOR TREATMENT OF CANCER
    Publication number: 20110044983
    Abstract: Methods for treating, preventing or delaying onset of tumor formation and other forms of cancer are disclosed. The methods involve administration of a complement inhibitor to inhibit C5a receptor signaling in the tumor microenvironment.
    Type: Application
    Filed: February 19, 2009
    Publication date: February 24, 2011
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: John D. Lambris, Maciej M. Markiewski
  • Potent compstatin analogs
    Patent number: 7888323
    Abstract: Compounds comprising peptides and peptidomimetics capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds.
    Type: Grant
    Filed: November 28, 2006
    Date of Patent: February 15, 2011
    Assignee: The Trustees Of The University Of Pennsylvania
    Inventors: John D. Lambris, Madan Katragadda
  • Method Of Reducing Tissue Loss In Pancreatic Islet Cell Transplantation
    Publication number: 20110008343
    Abstract: Methods for reducing rejection of pancreatic islet cells transplanted into a subject are disclosed. The methods involve transplanting pancreatic islet cells into a subject in the presence of a complement inhibitor, alone or combined with dextran sulfate.
    Type: Application
    Filed: June 6, 2008
    Publication date: January 13, 2011
    Inventors: John D. Lambris, Olie Korsgren, Bo Nillson
  • Complement-Mediated Thrombophilic Assay
    Publication number: 20100311086
    Abstract: A method for assessing the presence of an acquired thrombophilia disorder in a patient exhibiting hypercoagulation is disclosed.
    Type: Application
    Filed: June 25, 2008
    Publication date: December 9, 2010
    Inventors: John D. Lambris, Konstantinos Ritis
  • Compstatin analogs with improved activity
    Publication number: 20100222550
    Abstract: Compounds comprising peptides and peptidomimetics capable of binding the C3 protein and inhibiting complement activation are disclosed. These compounds display improved complement activation-inhibitory activity as compared with currently available compounds. Isolated nucleic acid molecules encoding the peptides are also disclosed.
    Type: Application
    Filed: September 22, 2003
    Publication date: September 2, 2010
    Inventor: John D. Lambris
  • Potent compstatin analogs
    Publication number: 20080227717
    Abstract: Compounds comprising peptides and peptidomimetics capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds.
    Type: Application
    Filed: November 28, 2006
    Publication date: September 18, 2008
    Inventors: John D. Lambris, Madan Katragadda